The genesis and evolution of high-grade serous ovarian cancer.
about
CD164 regulates the tumorigenesis of ovarian surface epithelial cells through the SDF-1α/CXCR4 axisVarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencingHistone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancerOvarian Cancer Molecular Stratification and Tumor Heterogeneity: A Necessity and a ChallengeEmerging and Evolving Ovarian Cancer Animal ModelsPrognostic Role of Serum Antibody Immunity to p53 Oncogenic Protein in Ovarian Cancer: A Systematic Review and a Meta-AnalysisThe PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challengesRegulation of ovarian cancer stem cells or tumor-initiating cellsCancer evolution: mathematical models and computational inferenceSociety of Gynecologic Oncology recommendations for the prevention of ovarian cancerStroma-associated master regulators of molecular subtypes predict patient prognosis in ovarian cancer.Preventing Damage Limitation: Targeting DNA-PKcs and DNA Double-Strand Break Repair Pathways for Ovarian Cancer TherapyThe long non-coding RNA ANRIL promotes proliferation and cell cycle progression and inhibits apoptosis and senescence in epithelial ovarian cancerMAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomasDiscovery of specific metastasis-related N-glycan alterations in epithelial ovarian cancer based on quantitative glycomicsHigh throughput interrogation of somatic mutations in high grade serous cancer of the ovaryIdentification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancerMolecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma.ZNF300P1 encodes a lincRNA that regulates cell polarity and is epigenetically silenced in type II epithelial ovarian cancerReducing confounding and suppression effects in TCGA data: an integrated analysis of chemotherapy response in ovarian cancer.A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway.Long noncoding RNA NBAT-1 suppresses tumorigenesis and predicts favorable prognosis in ovarian cancer.SOX2 is required to maintain cancer stem cells in ovarian cancer.Evaluation of ovarian function after hysterectomy with or without salpingectomy: A feasible study.Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancerCYP3A4 overexpression enhances the cytotoxicity of the antitumor triazoloacridinone derivative C-1305 in CHO cells.Oxysterols synergize with statins by inhibiting SREBP-2 in ovarian cancer cellsTetramethoxychalcone, a chalcone derivative, suppresses proliferation, blocks cell cycle progression, and induces apoptosis of human ovarian cancer cells.Lung adenocarcinoma of never smokers and smokers harbor differential regions of genetic alteration and exhibit different levels of genomic instability.TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions.MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma.Expression analysis of MIR182 and its associated target genes in advanced ovarian carcinoma.Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer.Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche.Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcomePredictive modeling using a somatic mutational profile in ovarian high grade serous carcinomaThe Wnt gatekeeper SFRP4 modulates EMT, cell migration and downstream Wnt signalling in serous ovarian cancer cellsMultiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinomaPaclitaxel resistance and multicellular spheroid formation are induced by kallikrein-related peptidase 4 in serous ovarian cancer cells in an ascites mimicking microenvironment.Molecular characterization of an intact p53 pathway subtype in high-grade serous ovarian cancer.
P2860
Q24337710-14D58D79-5AB9-455B-9DD4-EFDE670E35E3Q24628978-AE10F12F-B0A8-4836-83CF-1C9980D25BF0Q26777453-98BED444-10CD-4929-8B20-9961E0E9610BQ26777846-883344EF-B2DD-4989-9B8F-4C602416E19AQ26783909-4DDF15A1-2D00-4382-8E4C-EB13367F98EDQ26785421-7C51C0C7-E71E-4407-8890-B457D228DF01Q26851852-C178786F-09BF-4CFB-9CBB-D880F19DB27BQ26853096-5D371CA3-B2DD-4CDB-988D-906797FB60B8Q27002537-7EA5D558-E870-4E78-8CB7-74F6B3F0C49EQ27009306-48A9BB0D-921D-42F2-93FC-59B7604C5ACAQ27307642-7F02D8A7-B856-418A-818D-276B276C620CQ28084568-DEA32B73-FE1B-4465-AD9E-6251CBB8B2B8Q28392415-A0666F3B-836B-41BB-BE03-2F8DB28F7282Q28393224-D0D993FD-0212-4417-829A-BC3731C7D4E8Q28539618-003B8280-0EAC-4C75-BAF1-617C617487BBQ28740553-F13BEB52-3F48-40B8-8581-BDC790D95F20Q28741689-130C73E7-BEE7-4166-BE17-92BB268E1B75Q30430198-8B15AD01-E9EE-4F24-939D-0EDD13DD5F81Q30565514-D9198C96-BC4F-4BA7-BAFA-2457B6A6BAA8Q30576727-396A8AAC-7219-4D96-A703-6B117CD427D1Q31010361-A565B622-0C9B-43C5-A44E-9BA0E010320AQ33553490-8FE10880-0374-4FCF-ABEF-136E55505EACQ33607622-34494C8D-5BAA-4F86-AA2D-B5EBF9A61627Q33771168-1165E3D9-7109-43F4-A91A-061C6DF1AB98Q33787214-69E2A563-800B-4AB0-85D2-438A9C3A1D06Q33862351-9E7C707F-E5C2-409F-81A8-8AC57FACE8A1Q33917134-952506D2-F811-41C9-8105-B04306A39E61Q34121811-F47EF903-95B0-42A6-B17E-461F39ED60E8Q34193618-AD4AF475-D428-4F86-8949-7B8CA368B945Q34223292-C1FDEC05-A3B9-48CE-99FA-E4FBB772C289Q34253391-C125010B-1B27-4FCB-8D12-1326DAEB2098Q34287721-DE7797E7-3FE8-4693-A205-5A84AFED524AQ34305493-5D8E0077-6762-4768-9A71-B45D8E762C58Q34331396-5689592E-4868-4084-B969-CAFBCC161834Q34381630-B3296684-5701-4C4D-9958-77C2B63DA0EEQ34552129-2A0B178A-F321-4294-B50C-A3345742010EQ34552289-2F74AA0D-9501-431A-8E8B-B3925E488102Q34586019-8687FA14-FCBA-4E9C-A29A-67511F35478AQ34602948-0565631C-ADAC-4F25-990B-8EB9B746C7ECQ34612419-FCA29406-46D5-4071-9E2B-C05159483FE0
P2860
The genesis and evolution of high-grade serous ovarian cancer.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
The genesis and evolution of high-grade serous ovarian cancer.
@en
The genesis and evolution of high-grade serous ovarian cancer.
@nl
type
label
The genesis and evolution of high-grade serous ovarian cancer.
@en
The genesis and evolution of high-grade serous ovarian cancer.
@nl
prefLabel
The genesis and evolution of high-grade serous ovarian cancer.
@en
The genesis and evolution of high-grade serous ovarian cancer.
@nl
P356
P1476
The genesis and evolution of high-grade serous ovarian cancer.
@en
P2860
P2888
P304
P356
10.1038/NRC2946
P407
P577
2010-10-14T00:00:00Z
P6179
1009226044